Here we can show that median levels of tau and phosphorylated tau generally range higher in Alzheimer’s disease, vascular dementia and Lewy body disease whereby in contrast, median levels of amyloid-β1–42 are generally reduced in patients with Alzheimer’s disease and patients with Lewy body disease when compared with other disease groups here. Here, MAPT is linked to Alzheimer disease.